Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019
Jeremy A.W. Gold, Seda S. Tolu, Tom Chiller, Kaitlin Benedict, Brendan R. Jackson
Abstract
We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).
Topics & Concepts
IbrutinibIncidence (geometry)MedicineSmall moleculeInternal medicineLeukemiaBiologyChronic lymphocytic leukemiaPhysicsGeneticsOpticsChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune DisordersAutoimmune Bullous Skin Diseases